Everolimus Tablet Franchise in Ahmedabad

Everloop 2.5 mg Tablet Supplier in Mumbai

Immunosuppressant Tablet Distributor in Delhi

Everolimus Tablet Manufacturer in Bangalore

Transplant & Oncology Tablet Stockist in Hyderabad
Everolimus Tablet Exporter in Chandigarh

Home/Products /everolimus-2-5mg-tablet

Everloop 2.5 Tablet

Composition : Everolimus (2.5mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Everloop 2.5 Tablet contains Everolimus 2.5 mg, a high-potency mTOR inhibitor widely used in organ transplant medicine and certain oncology therapies. It is designed to prevent graft rejection by suppressing T-cell activation while controlling abnormal cell proliferation in selected cancer indications.

Everolimus works by modulating the mammalian target of rapamycin (mTOR) pathway, reducing immune overactivity and maintaining optimal graft survival. This tablet is ideal for patients requiring higher-dose immunosuppression under strict medical supervision.

Clinically, Everloop 2.5 Tablet is used in renal, liver, and other solid organ transplant regimens and in targeted oncology protocols, where precise dose titration is critical for efficacy and safety.

The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital supply chains, transplant centers, oncology clinics, and specialty pharmacies that demand high-quality immunosuppressive therapy.

Read More

About the Product

Everloop 2.5 Tablet contains Everolimus 2.5 mg, a high-potency mTOR inhibitor widely used in organ transplant medicine and certain oncology therapies. It is designed to prevent graft rejection by suppressing T-cell activation while controlling abnormal cell proliferation in selected cancer indications.

Everolimus works by modulating the mammalian target of rapamycin (mTOR) pathway, reducing immune overactivity and maintaining optimal graft survival. This tablet is ideal for patients requiring higher-dose immunosuppression under strict medical supervision.

Clinically, Everloop 2.5 Tablet is used in renal, liver, and other solid organ transplant regimens and in targeted oncology protocols, where precise dose titration is critical for efficacy and safety.

The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital supply chains, transplant centers, oncology clinics, and specialty pharmacies that demand high-quality immunosuppressive therapy.

Common side effects may include mouth ulcers, nausea, diarrhea, fatigue, rash, infections, and elevated lipid levels. Rare but serious side effects include delayed wound healing, lung toxicity, bone marrow suppression, and severe infections.

Everloop 2.5 Tablet is indicated for the prevention of organ transplant rejection in combination with other immunosuppressants. It is also prescribed for management of specific cancers and benign tumors, such as renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex–associated conditions, under specialist supervision.

Use Everloop 2.5 Tablet strictly as prescribed by a healthcare professional. Regular monitoring of blood counts, kidney function, lipid profile, and drug levels is essential. Inform your doctor about any current infections, liver disorders, or concurrent medications. Avoid live vaccines during therapy. Seek immediate medical attention if persistent fever, cough, shortness of breath, or other serious symptoms occur.

Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.

Get in Touch